Postoperative management of differentiated thyroid cancer.

[1]  G. Manciet,et al.  Low levels of serum thyroglobulin after withdrawal of thyroid suppression therapy in the follow up of differentiated thyroid carcinoma , 2005, European Journal of Nuclear Medicine.

[2]  H. Biersack,et al.  Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer , 1996, European Journal of Nuclear Medicine.

[3]  F. Cetani,et al.  Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine , 1994, World Journal of Surgery.

[4]  S. Larson,et al.  A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  A. Oberg,et al.  Papillary Thyroid Carcinoma Managed at the Mayo Clinic during Six Decades (1940–1999): Temporal Trends in Initial Therapy and Long-term Outcome in 2444 Consecutively Treated Patients , 2002, World Journal of Surgery.

[6]  S. Larson,et al.  Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? , 2002, The Journal of clinical endocrinology and metabolism.

[7]  R. Kloos,et al.  Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? , 2002, The Journal of clinical endocrinology and metabolism.

[8]  A. Pinchera,et al.  Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. , 2002, The Journal of clinical endocrinology and metabolism.

[9]  W. Mendenhall,et al.  Papillary thyroid carcinoma: prognostic factors and the role of radioiodine and external radiotherapy. , 2002, International journal of radiation oncology, biology, physics.

[10]  G. Lindstedt,et al.  Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone , 2002, Journal of endocrinological investigation.

[11]  J. Weissman,et al.  MRI Detection of Cervical Metastasis From Differentiated Thyroid Carcinoma , 2001, The Laryngoscope.

[12]  S. Larson,et al.  Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. , 2001, Thyroid : official journal of the American Thyroid Association.

[13]  S. Krishnamurthy,et al.  Ultrasound‐guided fine‐needle aspiration biopsy of the thyroid bed , 2001, Cancer.

[14]  S. Larson,et al.  Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. , 2001, The Journal of clinical endocrinology and metabolism.

[15]  L. Hann,et al.  Advances in the detection of residual thyroid carcinoma. , 2001, Advances in internal medicine.

[16]  R. Görges,et al.  Value of preoperative diagnostic modalities in patients with recurrent thyroid carcinoma. , 2000, Surgery.

[17]  O. Hoekstra,et al.  Positron emission tomography for the detection of metastases of differentiated thyroid carcinoma. , 2000, The Netherlands journal of medicine.

[18]  J. Llamas-Elvira,et al.  Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels. , 2000, American journal of surgery.

[19]  G. Coates,et al.  FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  S. Larson,et al.  Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. , 2000, The Journal of clinical endocrinology and metabolism.

[21]  A. King,et al.  Staging papillary carcinoma of the thyroid: magnetic resonance imaging vs ultrasound of the neck. , 2000, Clinical radiology.

[22]  E. Baudin,et al.  Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? , 2000, The Journal of clinical endocrinology and metabolism.

[23]  P. V. van Rijk,et al.  The detection of small carcinoma with 18F-FDG using a dual head coincidence camera. , 1999, European journal of radiology.

[24]  O. Schober,et al.  Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study , 1999, European Journal of Nuclear Medicine.

[25]  B. Weintraub,et al.  A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. , 1999, The Journal of clinical endocrinology and metabolism.

[26]  P. Ladenson,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 1999 by The Endocrine Society Quantitative Reverse Transcription-Polymerase Chain Reaction of Circulating Thyroglobulin Messenger Ribonucleic Acid for Monitoring Patients wit , 2022 .

[27]  R. Tambouret,et al.  Ultrasound‐guided fine‐needle aspiration biopsy of the thyroid , 1999, Cancer.

[28]  H. Biersack,et al.  Non-131I-scintigraphy in the treatment and follow-up of thyroid cancer. Single-photon-emitters or FDG-PET? , 1999, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[29]  Scott T. Grafton,et al.  Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. , 1999, Thyroid : official journal of the American Thyroid Association.

[30]  S. Larson,et al.  [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. , 1999, The Journal of clinical endocrinology and metabolism.

[31]  D. Lee,et al.  Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  M. Ringel,et al.  Quantitative reverse transcription-PCR measurement of thyroglobulin mRNA in peripheral blood of healthy subjects. , 1999, Clinical chemistry.

[33]  M. J. Pérez-Castejón,et al.  La PET-FDG en el cáncer de tiroides ante niveles altos de tiroglobulina y rastreo 131I negativo. A propósito de un caso , 1999 .

[34]  I. Fleming,et al.  A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985‐1995 , 1998, Cancer.

[35]  P. Ladenson,et al.  Molecular diagnosis of residual and recurrent thyroid cancer by amplification of thyroglobulin messenger ribonucleic acid in peripheral blood. , 1998, The Journal of clinical endocrinology and metabolism.

[36]  Y. Menda,et al.  Thallium-201, technetium-99m-tetrofosmin and iodine-131 in detecting differentiated thyroid carcinoma metastases. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[37]  P. Ladenson,et al.  Outcome after Treatment of High-Risk Papillary and Non-Hurthle-Cell Follicular Thyroid Carcinoma , 1998, Annals of Internal Medicine.

[38]  E. Baudin,et al.  Combination of radioiodine (131I) and probe-guided surgery for persistent or recurrent thyroid carcinoma. , 1998, The Journal of clinical endocrinology and metabolism.

[39]  P. Chieng,et al.  Positron emission tomography for detecting iodine-131 nonvisualized metastasis of well-differentiated thyroid carcinoma: Two case reports , 1998, Journal of endocrinological investigation.

[40]  H. Jadvar,et al.  Evaluation of suspected recurrent papillary thyroid carcinoma with [18F]fluorodeoxyglucose positron emission tomography. , 1998, Nuclear medicine communications.

[41]  P. Mikosch,et al.  Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[42]  O. Schober,et al.  Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans , 1998, Langenbeck's Archives of Surgery.

[43]  M. Clausen,et al.  Histological verification of positive fluorine-18 fluorodeoxyglucose findings in patients with differentiated thyroid cancer , 1998, Langenbeck's Archives of Surgery.

[44]  J. Rosai,et al.  Detection of thyroglobulin, thyroid peroxidase, and RET/PTC1 mRNA transcripts in the peripheral blood of patients with thyroid disease. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  S. Sone,et al.  Papillary thyroid carcinoma: MR diagnosis of lymph node metastasis. , 1998, AJNR. American journal of neuroradiology.

[46]  R. Tsang,et al.  The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma , 1998, Cancer.

[47]  P. Caron,et al.  Immunoradiometric Assay of Thyroglobulin in Patients with Differentiated Thyroid Carcinomas: Need for Thyroglobulin Recovery Tests , 1998, Clinical chemistry and laboratory medicine.

[48]  P. Ladenson,et al.  Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. , 1998, Thyroid : official journal of the American Thyroid Association.

[49]  P. Parrilla,et al.  High-resolution ultrasound associated with aspiration biopsy in the follow-up of patients with differentiated thyroid cancer , 1997, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[50]  M. Dietlein,et al.  Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer , 1997, European Journal of Nuclear Medicine.

[51]  J. Garber,et al.  Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. , 1997, The New England journal of medicine.

[52]  T. Mccaffrey,et al.  The surgical management of laryngotracheal invasion by well-differentiated papillary thyroid carcinoma. , 1997, Archives of otolaryngology--head & neck surgery.

[53]  C. Key,et al.  Prognostic factors for thyroid carcinoma , 1997, Cancer.

[54]  J. Chabot,et al.  Detection of circulating thyroid cells in peripheral blood. , 1996, Surgery.

[55]  J. Bringer,et al.  Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. , 1996, The Journal of clinical endocrinology and metabolism.

[56]  J. Hanke,et al.  Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[57]  C. Bal,et al.  Prospective randomized clinical trial to evaluate the optimal dose of 131I for remnant ablation in patients with differentiated thyroid carcinoma , 1996, Cancer.

[58]  M. Schlumberger,et al.  Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[59]  H. Sack,et al.  Differentiated thyroid cancer: Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4) , 1996, Cancer.

[60]  D. A. Meier,et al.  Cervical lymph node metastasis of thyroid papillary carcinoma imaged with fluorine-18-FDG, technetium-99m-pertechnetate and iodine-131-sodium iodide. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[61]  J. Hanke,et al.  [18FDG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131I]. , 1995, Nuklearmedizin. Nuclear medicine.

[62]  S. Jhiang,et al.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. , 1994, The American journal of medicine.

[63]  R. Tsang,et al.  Radioiodine ablation of residual tissue in thyroid cancer: relationship between administered activity, neck uptake and outcome. , 1994, The British journal of radiology.

[64]  G. Németh,et al.  Prophylactic external irradiation in differentiated thyroid cancer: a retrospective study over a 30-year observation period. , 1994, Oncology.

[65]  H. Wanebo,et al.  Recurrent Thyroid Cancer Role of Surgery Versus Radioactive Iodine (I131) , 1994, Annals of Surgery.

[66]  P. Ladenson,et al.  Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. , 1994, The Journal of clinical endocrinology and metabolism.

[67]  A. Avraham,et al.  Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[68]  R. A’Hern,et al.  Results of external beam radiotherapy in differentiated thyroid carcinoma: a retrospective study from the Royal Marsden Hospital. , 1994, European journal of cancer.

[69]  E. Bergstralh,et al.  Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. , 1993, Surgery.

[70]  P. van Houtte,et al.  Postoperative irradiation for thyroid cancer. , 1993, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[71]  E. Strong,et al.  Lobectomy versus total thyroidectomy for differentiated carcinoma of the thyroid: a matched-pair analysis. , 1993, American journal of surgery.

[72]  R. Wahl,et al.  Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy. , 1993, The Journal of clinical endocrinology and metabolism.

[73]  G. Masarotto,et al.  Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[74]  H. Hoshi,et al.  Detection of recurrent thyroid cancer: MR versus thallium-201 scintigraphy. , 1993, AJNR. American journal of neuroradiology.

[75]  C. Reiners,et al.  Surgical reintervention for differentiated thyroid cancer , 1993, The British journal of surgery.

[76]  Steven J Brown,et al.  The role of iodine‐131 and thallium‐201 imaging and serum thyroglobulin in the management of differentiated thyroid carcinoma , 1993, Cancer.

[77]  C. Begg,et al.  Prognostic factors in differentiated carcinoma of the thyroid gland. , 1992, American journal of surgery.

[78]  D. Johnston,et al.  The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. , 1992, The Journal of clinical endocrinology and metabolism.

[79]  V S Hertzberg,et al.  Radioiodine-131 therapy for well-differentiated thyroid cancer--a quantitative radiation dosimetric approach: outcome and validation in 85 patients. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[80]  W. Simpson,et al.  Management of local recurrence in well-differentiated thyroid carcinoma. , 1992, The Journal of surgical research.

[81]  E. Bergstralh,et al.  Papillary thyroid microcarcinoma : a study of 535 cases observed in a 50-year period: Discussion , 1992 .

[82]  K. Johansen,et al.  Comparison of 1073 MBq and 3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[83]  G. Ronga,et al.  Can iodine-131 whole-body scan be replaced by thyroglobulin measurement in the post-surgical follow-up of differentiated thyroid carcinoma? , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[84]  J. Chmiel,et al.  Survival discriminants for differentiated thyroid cancer. , 1990, American journal of surgery.

[85]  E. Kaplan,et al.  Natural history, treatment, and course of papillary thyroid carcinoma. , 1990, The Journal of clinical endocrinology and metabolism.

[86]  W. Sauerwein,et al.  Survival rates in patients with differentiated thyroid carcinoma. Influence of postoperative external radiotherapy , 1990, Cancer.

[87]  C. Marcocci,et al.  Clinical and biologic behavior of bone metastases from differentiated thyroid carcinoma. , 1989, Surgery.

[88]  B. Cady,et al.  An expanded view of risk-group definition in differentiated thyroid carcinoma. , 1988, Surgery.

[89]  I D Hay,et al.  Local recurrence in papillary thyroid carcinoma: is extent of surgical resection important? , 1988, Surgery.

[90]  D. F. Preston,et al.  Radioiodine therapy for differentiated thyroid carcinoma. , 1988, American journal of surgery.

[91]  E. Bergstralh,et al.  Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. , 1988, The Journal of clinical endocrinology and metabolism.

[92]  C. Higgins,et al.  Recurrent thyroid carcinoma: characteristics on MR images. , 1988, Radiology.

[93]  J. Charboneau,et al.  US-guided biopsy of neck masses in postoperative management of patients with thyroid cancer. , 1988, Radiology.

[94]  T. Panzarella,et al.  Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. , 1988, International journal of radiation oncology, biology, physics.

[95]  B. Cady,et al.  Surgically incurable well-differentiated thyroid carcinoma. Prognostic factors and results of therapy. , 1988, Archives of surgery.

[96]  W. Taylor,et al.  Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. , 1987, Surgery.

[97]  A. Pinchera,et al.  Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[98]  S. McKinney,et al.  Papillary and follicular thyroid cancer. Prognostic factors in 1,578 patients. , 1987, The American journal of medicine.

[99]  D. Kopans,et al.  Sonography in the follow-up of 100 patients with thyroid carcinoma. , 1987, AJR. American journal of roentgenology.

[100]  J. Ranstam,et al.  Is the EORTC prognostic index of thyroid cancer valid in differentiated thyroid carcinoma? Retrospective multivariate analysis of differentiated thyroid carcinoma with long follow‐up , 1986, Cancer.

[101]  G. Braunstein,et al.  Evaluation of Low-Dose Radioiodine Ablation Therapy in Postsurgical Thyroid Cancer Patients , 1985, Clinical nuclear medicine.

[102]  A. Pinchera,et al.  DIAGNOSTIC VALUE OF A SINGLE SERUM THYROGLOBULIN DETERMINATION ON AND OFF THYROID SUPPRESSIVE THERAPY IN THE FOLLOW‐UP OF PATIENTS WITH DIFFERENTIATED THYROID CANCER , 1985, Clinical endocrinology.

[103]  M. Schlumberger,et al.  External radiotherapy in thyroid cancers , 1985, Cancer.

[104]  D. Berman,et al.  Correlation of thyroglobulin measurements and radioiodine scans in the follow‐up of patients with differentiated thyroid cancer , 1985, Cancer.

[105]  N. Ordóñez,et al.  Pulmonary metastasis of differentiated thyroid carcinoma: treatment results in 101 patients. , 1985, The Journal of clinical endocrinology and metabolism.

[106]  R. Lloyd,et al.  An analysis of "ablation of thyroid remnants" with I-131 in 511 patients from 1947-1984: experience at University of Michigan. , 1984, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[107]  D. Donohoe,et al.  Thyroglobulin may be undetectable in the serum of patients with metastatic disease secondary to differentiated thyroid carcinoma. Follow‐up of differentiated thyroid carcinoma , 1984, Cancer.

[108]  V. R. McCready,et al.  Radioiodine treatment of metastatic thyroid carcinoma: the Royal Marsden Hospital experience. , 1984, The British journal of radiology.

[109]  G. Guiraudon,et al.  Pulmonary metastases in differentiated thyroid carcinoma. Study of 58 cases with implications for the primary tumor treatment , 1984, Cancer.

[110]  R. Gelman,et al.  The effect of thyroid hormone administration upon survival in patients with differentiated thyroid carcinoma. , 1983, Surgery.

[111]  S. Refetoff,et al.  The value of serum thyroglobulin measurement in clinical practice. , 1983, JAMA.

[112]  V S Hertzberg,et al.  Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. , 1983, The New England journal of medicine.

[113]  C. Gorman,et al.  Thyroid remnant ablation: questionable pursuit of an ill-defined goal. , 1983, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[114]  L. Degroot,et al.  Comparison of 30- and 50-mCi doses of iodine-131 for thyroid ablation. , 1982, Annals of internal medicine.

[115]  M. Ashcraft,et al.  The comparative value of serum thyroglobulin measurements and iodine 131 total body scans in the follow-up study of patients with treated differentiated thyroid cancer. , 1981, The American journal of medicine.

[116]  E. Mazzaferri,et al.  Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. , 1981, The American journal of medicine.

[117]  N. Samaan,et al.  131I therapy in differentiated thyroid carcinoma: M. D. Anderson hospital experience , 1981 .

[118]  B. Cady,et al.  Changing Clinical, Pathologic, Therapeutic, and Survival Patterns in Differentiated Thyroid Carcinoma , 1976, Annals of surgery.

[119]  R. Adler,et al.  Low dose radioiodide thyroid ablation in postsurgical patients with thyroid cancer. , 1976, The American journal of medicine.

[120]  J. Shah,et al.  Papillary carcinoma of the thyroid , 1963 .